Stem cell-based therapy for Huntington's disease

Journal of Cellular Biochemistry

Volumn 114, Issue 4, 2013, Pages 754-763

  Maucksch, Christof ^a   Vazey, Elena M ^a   Gordon, Renee J ^a   Connor, Bronwen ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

HUNTINGTON'S DISEASE; RODENT HD MODEL; STEM CELLS; TRANSPLANTATION

Indexed keywords

NEUROTROPHIC FACTOR;

ADIPOSE DERIVED STEM CELL; ALLOGRAFT; ANIMAL MODEL; HUMAN; HUNTINGTON CHOREA; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; XENOGRAFT;

ADIPOSE TISSUE; ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DIFFERENTIATION; GABAERGIC NEURONS; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; NEURAL STEM CELLS; RATS; REPETITIVE SEQUENCES, NUCLEIC ACID; STEM CELL TRANSPLANTATION;

EID: 84874245374     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24432     Document Type: Review

References (108)

1. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL,. 2008. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci USA 105: 16707-16712.
2. Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boisse MF, Grandmougin T, Jeny R, Bartolomeo P, Dalla Barba G, Degos JD, Lisovoski F, Ergis AM, Pailhous E, Cesaro P, Hantraye P, Peschanski M,. 2000. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356: 1975-1979.
3. Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, Baudic S, Ribeiro MJ, Bourdet C, Remy P, Cesaro P, Hantraye P, Peschanski M,. 2006. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: A long-term follow-up study. Lancet Neurol 5: 303-309.
4. Bantubungi K, Blum D, Cuvelier L, Wislet-Gendebien S, Rogister B, Brouillet E, Schiffmann SN,. 2008. Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. Mol Cell Neurosci 37: 454-470.
5. Bates GP, Harper PS, Jones AL,. 2002. Huntington's disease, 3rd edition. New York: Oxford University Press. p 558.
6. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW,. 1991. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11: 1649-1659.
7. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT,. 1993. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192.
8. Blum D, Gall D, Cuvelier L, Schiffmann SN,. 2001. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 12: 1769-1772.
9. Borlongan CV, Koutouzis TK, Freeman TB, Hauser RA, Cahill DW, Sanberg PR,. 1997. Hyperactivity and hypoactivity in a rat model of Huntington's disease: The systemic 3-nitropropionic acid model. Brain Res Brain Res Protoc 1: 253-257.
10. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA,. 1996. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 46: 527-531.
11. Brignull HR, Morley JF, Garcia SM, Morimoto RI,. 2006. Modeling polyglutamine pathogenesis in C. elegans. Methods Enzymol 412: 256-282.
12. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF,. 1995. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92: 7105-7109.
13. Choong PF, Mok PL, Cheong SK, Leong CF, Then KY,. 2007. Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy 9: 170-183.
14. Clarke DJ, Dunnett SB, Isacson O, Bjorklund A,. 1988a. Striatal grafts in the ibotenic acid-lesioned neostriatum: Ultrastructural and immunocytochemical studies. Prog Brain Res 78: 47-53.
15. Clarke DJ, Dunnett SB, Isacson O, Sirinathsinghji DJ, Bjorklund A,. 1988b. Striatal grafts in rats with unilateral neostriatal lesions-I. Ultrastructural evidence of afferent synaptic inputs from the host nigrostriatal pathway. Neuroscience 24: 791-801.
16. de la Monte SM, Vonsattel JP, Richardson EP, Jr., 1988. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47: 516-525.
17. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL,. 2010. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 214: 193-200.
18. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel JP, Carraway R, Reeves SA, Boyce FM, Aronin N,. 1995. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14: 1075-1081.
19. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N,. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
20. Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M,. 2010. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 170: 324-336.
21. Dragatsis I, Levine MS, Zeitlin S,. 2000. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26: 300-306.
22. Dunnett SB, Rosser AE,. 2007. Cell transplantation for Huntington's disease Should we continue ? Brain Res Bull 72: 132-147.
23. Dunnett SB, Isacson O, Sirinathsinghji DJ, Clarke DJ, Bjorklund A,. 1988a. Striatal grafts in rats with unilateral neostriatal lesions-III. Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching. Neuroscience 24: 813-820.
24. Dunnett SB, Isacson O, Sirinathsinghji DJ, Clarke DJ, Bjorklund A,. 1988b. Striatal grafts in the ibotenic acid-lesioned neostriatum: Functional studies. Prog Brain Res 78: 39-45.
25. Dunnett SB, Nathwani F, Bjorklund A,. 2000. The integration and function of striatal grafts. Prog Brain Res 127: 345-380.
26. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, Ge P, Vonsattel JP, Gusella JF, Joyner AL, et al. 1995. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269: 407-410.
27. Erba P, Terenghi G, Kingham PJ,. 2010. Neural differentiation and therapeutic potential of adipose tissue derived stem cells. Curr Stem Cell Res Ther 5: 153-160.
28. Farrington M, Wreghitt TG, Lever AM, Dunnett SB, Rosser AE, Barker RA,. 2006. Neural transplantation in Huntington's disease: The NEST-UK donor tissue microbiological screening program and review of the literature. Cell Transplant 15: 279-294.
29. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, Isacson O,. 2000a. Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology. Proc Natl Acad Sci USA 97: 13877-13882.
30. Freeman TB, Hauser RA, Willing AE, Zigova T, Sanberg PR, Saporta S,. 2000b. Transplantation of human fetal striatal tissue in Huntington's disease: Rationale for clinical studies. Novartis Found Symp 231: 129-138, discussion 139-47.
31. Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, Freeman TB, Stoessl AJ,. 2005. Positron emission tomography after fetal transplantation in Huntington's disease. Ann Neurol 58: 331-337.
32. Gallina P, Paganini M, Lombardini L, Saccardi R, Marini M, De Cristofaro MT, Pinzani P, Salvianti F, Crescioli C, Di Rita A, Bucciantini S, Mechi C, Sarchielli E, Moretti M, Piacentini S, Gritti G, Bosi A, Sorbi S, Orlandini G, Vannelli GB, Di Lorenzo N,. 2008. Development of human striatal anlagen after transplantation in a patient with Huntington's disease. Exp Neurol 313: 241-244.
33. Gaura V, Bachoud-Levi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, Brugieres P, Mangin JF, Boisse MF, Palfi S, Cesaro P, Samson Y, Hantraye P, Peschanski M, Remy P,. 2004. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 127: 65-72.
34. Gordon RJ, McGregor AL, Connor B,. 2009. Chemokines direct neural progenitor cell migration following striatal cell loss. Mol Cell Neurosci 41: 219-232.
35. Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E,. 1998. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 154: 663-672.
36. Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB,. 2002. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58: 687-695.
37. Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P,. 2009. Tetrabenazine. Nat Rev Drug Discov 8: 17-18.
38. Heng MY, Detloff PJ, Albin RL,. 2008. Rodent genetic models of Huntington disease. Neurobiol Dis 32: 1-9.
39. Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF,. 2005. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 20: 1-11.
40. Im W, Lee ST, Park JE, Oh HJ, Shim J, Lim J, Chu K, Kim M,. 2010. Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice. PLoS 2: RRN1183.
41. Isacson O, Breakefield XO,. 1997. Benefits and risks of hosting animal cells in the human brain. Nat Med 3: 964-969.
42. Isacson O, Dunnett SB, Bjorklund A,. 1986. Graft-induced behavioral recovery in an animal model of Huntington disease. Proc Natl Acad Sci USA 83: 2728-2732.
43. Johann V, Schiefer J, Sass C, Mey J, Brook G, Kruttgen A, Schlangen C, Bernreuther C, Schachner M, Dihne M, Kosinski CM,. 2007. Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington's disease. Exp Brain Res 177: 458-470.
44. Kassubek J, Gaus W, Landwehrmeyer GB,. 2004. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology 62: 523-524, author reply 524.
45. Kendall AL, Hantraye P, Palfi S,. 2000. Striatal tissue transplantation in non-human primates. Prog Brain Res 127: 381-404.
46. Krystkowiak P, Gaura V, Labalette M, Rialland A, Remy P, Peschanski M, Bachoud-Levi AC,. 2007. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS ONE 2: e166.
47. Kwan W, Magnusson A, Chou A, Adame A, Carson MJ, Kohsaka S, Masliah E, Moller T, Ransohoff R, Tabrizi SJ, Bjorkqvist M, Muchowski PJ,. 2012. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci 32: 133-142.
48. Lange H, Thorner G, Hopf A, Schroder KF,. 1976. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 28: 401-425.
49. Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR,. 2001. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 68: 313-324.
50. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR,. 2006. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96: 1121-1129.
51. Lee WC, Yoshihara M, Littleton JT,. 2004. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci USA 101: 3224-3229.
52. Lee ST, Chu K, Park JE, Lee K, Kang L, Kim SU, Kim M,. 2005. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model. Neurosci Res 52: 243-249.
53. Lee ST, Park JE, Lee K, Kang L, Chu K, Kim SU, Kim M, Roh JK,. 2006. Noninvasive method of immortalized neural stem-like cell transplantation in an experimental model of Huntington's disease. J Neurosci Methods 152: 250-254.
54. Lee ST, Chu K, Jung KH, Im WS, Park JE, Lim HC, Won CH, Shin SH, Lee SK, Kim M, Roh JK,. 2009. Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann Neurol 66: 671-681.
55. Lescaudron L, Unni D, Dunbar GL,. 2003. Autologous adult bone marrow stem cell transplantation in an animal model of huntington's disease: Behavioral and morphological outcomes. Int J Neurosci 113: 945-956.
56. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF,. 1999. Enhanced sensitivity to N-methyl- D -aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58: 515-532.
57. Li SH, Li XJ,. 2004. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20: 146-154.
58. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ,. 2001. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10: 137-144.
59. Lin YT, Chern Y, Shen CK, Wen HL, Chang YC, Li H, Cheng TH, Hsieh-Li HM,. 2011. Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS ONE 6: e22924.
60. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B,. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983.
61. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP,. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
62. Martinez-Serrano A, Bjorklund A,. 1996. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci 16: 4604-4616.
63. McBride JL, Behrstock SP, Chen EY, Jakel RJ, Siegel I, Svendsen CN, Kordower JH,. 2004. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol 475: 211-219.
64. Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF,. 2002. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 22: 8266-8276.
65. Morton AJ, Lagan MA, Skepper JN, Dunnett SB,. 2000. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J Neurocytol 29: 679-702.
66. Myers RH, Sax DS, Schoenfeld M, Bird ED, Wolf PA, Vonsattel JP, White RF, Martin JB,. 1985. Late onset of Huntington's disease. J Neurol Neurosurg Psychiatry 48: 530-534.
67. Nakao N, Itakura T,. 2000. Fetal tissue transplants in animal models of Huntington's disease: The effects on damaged neuronal circuitry and behavioral deficits. Prog Neurobiol 61: 313-338.
68. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR,. 1995. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81: 811-823.
69. Naver B, Stub C, Moller M, Fenger K, Hansen AK, Hasholt L, Sorensen SA,. 2003. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122: 1049-1057.
70. Nguyen HP, Kobbe P, Rahne H, Worpel T, Jager B, Stephan M, Pabst R, Holzmann C, Riess O, Korr H, Kantor O, Petrasch-Parwez E, Wetzel R, Osmand A, von Horsten S,. 2006. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum Mol Genet 15: 3177-3194.
71. Palfi S, Conde F, Riche D, Brouillet E, Dautry C, Mittoux V, Chibois A, Peschanski M, Hantraye P,. 1998. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 4: 963-966.
72. Pang TY, Du X, Zajac MS, Howard ML, Hannan AJ,. 2009. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet 18: 753-766.
73. Pineda JR, Rubio N, Akerud P, Urban N, Badimon L, Arenas E, Alberch J, Blanco J, Canals JM,. 2007. Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: Optical neuroimage tracking of brain-grafted cells. Gene Ther 14: 118-128.
74. Pritzel M, Isacson O, Brundin P, Wiklund L, Bjorklund A,. 1986. Afferent and efferent connections of striatal grafts implanted into the ibotenic acid lesioned neostriatum in adult rats. Exp Brain Res 65: 112-126.
75. Ramaswamy S, McBride JL, Kordower JH,. 2007a. Animal models of Huntington's disease. ILAR J 48: 356-373.
76. Ramaswamy S, Shannon KM, Kordower JH,. 2007b. Huntington's disease: Pathological mechanisms and therapeutic strategies. Cell Transplant 16: 301-312.
77. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, March KL,. 2004. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109: 1292-1298.
78. Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason S, Polkey CE, Clough C, Brooks DJ, Barker RA, Piccini P,. 2008. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry 79: 948-951.
79. Roberts TJ, Price J, Williams SC, Modo M,. 2006. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease. Neuroscience 139: 1187-1199.
80. Rosser AE, Dunnett SB,. 2003. Neural transplantation in patients with Huntington's disease. CNS Drugs 17: 853-867.
81. Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB,. 2002. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 73: 678-685.
82. Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, Connarty M, Crauford D, Curtis A, Curtis D, Davidson MJ, Differ AM, Dode C, Dodge A, Frontali M, Ranen NG, Stine OC, Sherr M, Abbott MH, Franz ML, Graham CA, Harper PS, Hedreen JC, Hayden MR, et al. 1996. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59: 16-22.
83. Ryu JK, Kim J, Cho SJ, Hatori K, Nagai A, Choi HB, Lee MC, McLarnon JG, Kim SU,. 2004. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis 16: 68-77.
84. Schwarcz R, Okuno E, White RJ, Bird ED, Whetsell WO, Jr., 1988. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc Natl Acad Sci USA 85: 4079-4081.
85. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A, et al. 1995. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14: 1065-1074.
86. Sirinathsinghji DJ, Dunnett SB, Isacson O, Clarke DJ, Kendrick K, Bjorklund A,. 1988. Striatal grafts in rats with unilateral neostriatal lesions-II. In vivo monitoring of GABA release in globus pallidus and substantia nigra. Neuroscience 24: 803-811.
87. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR,. 2003. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555-1567.
88. Snyder BR, Chiu AM, Prockop DJ, Chan AW,. 2010. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS ONE 5: e9347.
89. Song J, Lee ST, Kang W, Park JE, Chu K, Lee SE, Hwang T, Chung H, Kim M,. 2007. Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions. Neurosci Lett 423: 58-61.
90. Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ,. 2005. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 490: 354-370.
91. Tatter SB, Galpern WR, Hoogeveen AT, Isacson O,. 1995. Effects of striatal excitotoxicity on huntingtin-like immunoreactivity. Neuroreport 6: 1125-1129.
92. Thu DC, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RL,. 2010. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 133: 1094-1110.
93. van Dijk JG, van der Velde EA, Roos RA, Bruyn GW,. 1986. Juvenile Huntington disease. Hum Genet 73: 235-239.
94. Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR,. 2005. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 25: 4169-4180.
95. Vazey EM, Connor B,. 2010. Differential fate and functional outcome of lithium chloride primed adult neural progenitor cell transplants in a rat model of Huntington disease. Stem Cell Res Ther 1: 41.
96. Vazey EM, Chen K, Hughes SM, Connor B,. 2006. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease. Exp Neurol 199: 384-396.
97. Vazey EM, Dottori M, Jamshidi P, Tomas D, Pera MF, Horne M, Connor B,. 2010. Comparison of transplant efficiency between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington's disease. Cell Transplant 19: 1055-1062.
98. von Horsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AM, Paul M, Jones L, Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O,. 2003. Transgenic rat model of Huntington's disease. Hum Mol Genet 12: 617-624.
99. Vonsattel JP, DiFiglia M,. 1998. Huntington disease. J Neuropathol Exp Neurol 57: 369-384.
100. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr., 1985. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577.
101. Walker FO,. 2007. Huntington's disease. Lancet 369: 218-228.
102. Wang M, Crisostomo PR, Herring C, Meldrum KK, Meldrum DR,. 2006. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 291: R880-R884.
103. Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S, Friedlander RM, Gusella JF, Vonsattel JP, Borchelt DR, MacDonald ME,. 2002. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11: 633-640.
104. Yang L, Calingasan NY, Chen J, Ley JJ, Becker DA, Beal MF,. 2005. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp Neurol 191: 86-93.
105. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW,. 2008. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453: 921-924.
106. Zavan B, Vindigni V, Gardin C, D'Avella D, Della Puppa A, Abatangelo G, Cortivo R,. 2010. Neural potential of adipose stem cells. Discov Med 10: 37-43.
107. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A,. 1995. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11: 155-163.
108. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E,. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498.